Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 2623 entries
Sorted by: Best Match Show Resources per page
Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation.

Cureus

Shah R, Witt D, Asif T, Mir FF.
PMID: 28533998
Cureus. 2017 Apr 20;9(4):e1182. doi: 10.7759/cureus.1182.

Ipilimumab is a human monoclonal antibody that functions as a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor that is used to treat malignant melanoma. Due to ipilimumab's removal of immune regulation, specifically through the inactivation of CTLA-4, it is commonly...

Cite
Shah R, Witt D, Asif T, et al. Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation. Cureus. 2017;9(4):e1182doi: 10.7759/cureus.1182.
Shah, R., Witt, D., Asif, T., & Mir, F. F. (2017). Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation. Cureus, 9(4), e1182. https://doi.org/10.7759/cureus.1182
Shah, Raj, et al. "Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation." Cureus vol. 9,4 (2017): e1182. doi: https://doi.org/10.7759/cureus.1182
Shah R, Witt D, Asif T, Mir FF. Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation. Cureus. 2017 Apr 20;9(4):e1182. doi: 10.7759/cureus.1182. PMID: 28533998; PMCID: PMC5438238.
Copy Download .nbib Format: NLM
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.

Arthritis research & therapy

Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR.
PMID: 27655411
Arthritis Res Ther. 2016 Sep 22;18(1):210. doi: 10.1186/s13075-016-1109-8.

BACKGROUND: In the present study, we compared the incidence of hospitalized infection among children with juvenile idiopathic arthritis (JIA) following initiation of treatment with biologic agents versus methotrexate (MTX).METHODS: We used national Medicaid claims data from 2000 through 2010...

Cite
Beukelman T, Xie F, Baddley JW, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016;18(1):210doi: 10.1186/s13075-016-1109-8.
Beukelman, T., Xie, F., Baddley, J. W., Chen, L., Mannion, M. L., Saag, K. G., Zhang, J., & Curtis, J. R. (2016). The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis research & therapy, 18(1), 210. https://doi.org/10.1186/s13075-016-1109-8
Beukelman, Timothy, et al. "The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis." Arthritis research & therapy vol. 18,1 (2016): 210. doi: https://doi.org/10.1186/s13075-016-1109-8
Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016 Sep 22;18(1):210. doi: 10.1186/s13075-016-1109-8. PMID: 27655411; PMCID: PMC5032246.
Copy Download .nbib Format: NLM
Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogs.

Veterinary medicine and science

Mercier M, Barnes Heller HL.
PMID: 29067170
Vet Med Sci. 2015 Jun 29;1(1):16-22. doi: 10.1002/vms3.4. eCollection 2015 Jul.

Canine non-infectious, inflammatory meningoencephalomyelitis is termed meningoencephalomyelitis of unknown etiology (MUE) and may affect dogs of any age, breed or gender. Treatment with immunosuppressive medication has been widely reported, however no prospective clinical trials with a standard glucocorticoid monotherapy...

Cite
Mercier M, Barnes Heller HL. Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogs. Vet Med Sci. 2015;1(1):16-22doi: 10.1002/vms3.4.
Mercier, M., & Barnes Heller, H. L. (2015). Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogs. Veterinary medicine and science, 1(1), 16-22. https://doi.org/10.1002/vms3.4
Mercier, Miyu, and Barnes Heller, Heidi L. "Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogs." Veterinary medicine and science vol. 1,1 (2015): 16-22. doi: https://doi.org/10.1002/vms3.4
Mercier M, Barnes Heller HL. Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogs. Vet Med Sci. 2015 Jun 29;1(1):16-22. doi: 10.1002/vms3.4. eCollection 2015 Jul. PMID: 29067170; PMCID: PMC5645807.
Copy Download .nbib Format: NLM
Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone.

Case reports in oncology

Piraino FF.
PMID: 29515399
Case Rep Oncol. 2017 Nov 28;10(3):1076-1084. doi: 10.1159/000484714. eCollection 2017.

A 74-year-old female was diagnosed with the autoimmune inflammatory disease temporal arteritis and treated with high and low doses of prednisone over a period of 6 years. During that time, she developed cancers of the lung and colon as...

Cite
Piraino FF. Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone. Case Rep Oncol. 2017;10(3):1076-1084doi: 10.1159/000484714.
Piraino, F. F. (2017). Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone. Case reports in oncology, 10(3), 1076-1084. https://doi.org/10.1159/000484714
Piraino, Frank F. "Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone." Case reports in oncology vol. 10,3 (2017): 1076-1084. doi: https://doi.org/10.1159/000484714
Piraino FF. Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone. Case Rep Oncol. 2017 Nov 28;10(3):1076-1084. doi: 10.1159/000484714. eCollection 2017. PMID: 29515399; PMCID: PMC5836169.
Copy Download .nbib Format: NLM
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Seminars in oncology

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.
PMID: 28140093
Semin Oncol. 2002 Feb;29(1):56-69. doi: 10.1053/sonc.2002.30143.

Advanced-stage mantle cell lymphoma (MCL) is a disease for which no curative treatment strategy exists. Results with standard combination chemotherapy, with or without an anthracycline, are disappointing, and new and better therapies are needed. High-dose therapy and autologous stem-cell...

Cite
Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002;29(1):56-69doi: 10.1053/sonc.2002.30143.
Mangel, J., Buckstein, R., Imrie, K., Spaner, D., Crump, M., Tompkins, K., Reis, M., Perez-Ordonez, B., Deodhare, S., Romans, R., Pennell, N., Robinson, J. B., Hewitt, K., Richardson, P., Lima, A., Pavlin, P., & Berinstein, N. L. (2002). Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Seminars in oncology, 29(1), 56-69. https://doi.org/10.1053/sonc.2002.30143
Mangel, Joy, et al. "Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma." Seminars in oncology vol. 29,1 (2002): 56-69. doi: https://doi.org/10.1053/sonc.2002.30143
Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol. 2002 Feb;29(1):56-69. doi: 10.1053/sonc.2002.30143. PMID: 28140093.
Copy Download .nbib Format: NLM
Kidney biopsy for renal tubular acidosis: when tissue diagnosis makes a difference.

Clinical nephrology. Case studies

Humayun Y, Sanchez P, Norris LT, Monga D, Lewin J, Fülöp T.
PMID: 29043125
Clin Nephrol Case Stud. 2015 May 22;3:1-4. doi: 10.5414/CNCS108412. eCollection 2015.

Renal tubular acidosis (RTA) is a disorder with variable presentations and oftentimes a nebulous underlying primary diagnosis. We describe a rare cause of RTA as an unusual complication of proton pump inhibitor (PPI) therapy. We report a case of...

Cite
Humayun Y, Sanchez P, Norris LT, et al. Kidney biopsy for renal tubular acidosis: when tissue diagnosis makes a difference. Clin Nephrol Case Stud. 2015;3:1-4doi: 10.5414/CNCS108412.
Humayun, Y., Sanchez, P., Norris, L. T., Monga, D., Lewin, J., & Fülöp, T. (2015). Kidney biopsy for renal tubular acidosis: when tissue diagnosis makes a difference. Clinical nephrology. Case studies, 31-4. https://doi.org/10.5414/CNCS108412
Humayun, Youshay, et al. "Kidney biopsy for renal tubular acidosis: when tissue diagnosis makes a difference." Clinical nephrology. Case studies vol. 3 (2015): 1-4. doi: https://doi.org/10.5414/CNCS108412
Humayun Y, Sanchez P, Norris LT, Monga D, Lewin J, Fülöp T. Kidney biopsy for renal tubular acidosis: when tissue diagnosis makes a difference. Clin Nephrol Case Stud. 2015 May 22;3:1-4. doi: 10.5414/CNCS108412. eCollection 2015. PMID: 29043125; PMCID: PMC5438002.
Copy Download .nbib Format: NLM
Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

Current oncology (Toronto, Ont.)

MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH.
PMID: 28050137
Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21.

With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and...

Cite
MacDonald D, Prica A, Assouline S, et al. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016;23(6):407-417doi: 10.3747/co.23.3405.
MacDonald, D., Prica, A., Assouline, S., Christofides, A., Lawrence, T., & Sehn, L. H. (2016). Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Current oncology (Toronto, Ont.), 23(6), 407-417. https://doi.org/10.3747/co.23.3405
MacDonald, D, et al. "Emerging therapies for the treatment of relapsed or refractory follicular lymphoma." Current oncology (Toronto, Ont.) vol. 23,6 (2016): 407-417. doi: https://doi.org/10.3747/co.23.3405
MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21. PMID: 28050137; PMCID: PMC5176374.
Copy Download .nbib Format: NLM
Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma.

Clinical nephrology. Case studies

Miyata KN, Siddiqi NA, Kiss LP, Harbord NB, Winchester JF.
PMID: 29043141
Clin Nephrol Case Stud. 2017 Feb 03;5:9-15. doi: 10.5414/CNCS109036. eCollection 2017.

Renal involvement in non-Hodgkin lymphoma, especially mantle cell lymphoma (MCL) is rare. A 77-year-old man presented with acute kidney injury (AKI), which rapidly progressed to dialysis dependence. Kidney biopsy revealed patchy B-cell lymphocytic aggregates in the interstitium, which were...

Cite
Miyata KN, Siddiqi NA, Kiss LP, et al. Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clin Nephrol Case Stud. 2017;5:9-15doi: 10.5414/CNCS109036.
Miyata, K. N., Siddiqi, N. A., Kiss, L. P., Harbord, N. B., & Winchester, J. F. (2017). Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clinical nephrology. Case studies, 59-15. https://doi.org/10.5414/CNCS109036
Miyata, Kana N, et al. "Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma." Clinical nephrology. Case studies vol. 5 (2017): 9-15. doi: https://doi.org/10.5414/CNCS109036
Miyata KN, Siddiqi NA, Kiss LP, Harbord NB, Winchester JF. Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. Clin Nephrol Case Stud. 2017 Feb 03;5:9-15. doi: 10.5414/CNCS109036. eCollection 2017. PMID: 29043141; PMCID: PMC5438003.
Copy Download .nbib Format: NLM
Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis.

Clinical nephrology. Case studies

Sheta M, Riad S, Deepak U, Issa N, Birkenbach M, Ibrahim HN, Kukla A.
PMID: 29043142
Clin Nephrol Case Stud. 2017 Feb 17;5:16-19. doi: 10.5414/CNCS108875. eCollection 2017.

The best approach to treatment of de-novo rheumatoid arthritis in solid organ transplant recipients on typical immunosuppression is not well established. The use of biologics targeting specific cell types, cytokines, and immunological pathways has been gaining interest in the...

Cite
Sheta M, Riad S, Deepak U, et al. Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis. Clin Nephrol Case Stud. 2017;5:16-19doi: 10.5414/CNCS108875.
Sheta, M., Riad, S., Deepak, U., Issa, N., Birkenbach, M., Ibrahim, H. N., & Kukla, A. (2017). Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis. Clinical nephrology. Case studies, 516-19. https://doi.org/10.5414/CNCS108875
Sheta, Mohamed, et al. "Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis." Clinical nephrology. Case studies vol. 5 (2017): 16-19. doi: https://doi.org/10.5414/CNCS108875
Sheta M, Riad S, Deepak U, Issa N, Birkenbach M, Ibrahim HN, Kukla A. Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis. Clin Nephrol Case Stud. 2017 Feb 17;5:16-19. doi: 10.5414/CNCS108875. eCollection 2017. PMID: 29043142; PMCID: PMC5438010.
Copy Download .nbib Format: NLM
Esophageal Cicatricial Pemphigoid as an Isolated Involvement Treated with Mycophenolate Mofetil.

Case reports in gastrointestinal medicine

Sánchez Prudencio S, Domingo Senra D, Martín Rodríguez D, Botella Mateu B, Esteban Jiménez-Zarza C, de la Morena López F, Jiménez Reyes J, Nevado Santos M, de Cuenca Morón B.
PMID: 26557393
Case Rep Gastrointest Med. 2015;2015:620374. doi: 10.1155/2015/620374. Epub 2015 Oct 18.

Cicatricial pemphigoid (CP) is a rare blistering autoimmune disease. Esophageal involvement occurs in widespread disease and rarely appears as the only affected organ. We report a 67-year-old Caucasian female with esophageal dysphagia and weight loss. Several oral panendoscopies showed...

Cite
Sánchez Prudencio S, Domingo Senra D, Martín Rodríguez D, et al. Esophageal Cicatricial Pemphigoid as an Isolated Involvement Treated with Mycophenolate Mofetil. Case Rep Gastrointest Med. 2015;2015:620374doi: 10.1155/2015/620374.
Sánchez Prudencio, S., Domingo Senra, D., Martín Rodríguez, D., Botella Mateu, B., Esteban Jiménez-Zarza, C., de la Morena López, F., Jiménez Reyes, J., Nevado Santos, M., & de Cuenca Morón, B. (2015). Esophageal Cicatricial Pemphigoid as an Isolated Involvement Treated with Mycophenolate Mofetil. Case reports in gastrointestinal medicine, 2015620374. https://doi.org/10.1155/2015/620374
Sánchez Prudencio, Sandra, et al. "Esophageal Cicatricial Pemphigoid as an Isolated Involvement Treated with Mycophenolate Mofetil." Case reports in gastrointestinal medicine vol. 2015 (2015): 620374. doi: https://doi.org/10.1155/2015/620374
Sánchez Prudencio S, Domingo Senra D, Martín Rodríguez D, Botella Mateu B, Esteban Jiménez-Zarza C, de la Morena López F, Jiménez Reyes J, Nevado Santos M, de Cuenca Morón B. Esophageal Cicatricial Pemphigoid as an Isolated Involvement Treated with Mycophenolate Mofetil. Case Rep Gastrointest Med. 2015;2015:620374. doi: 10.1155/2015/620374. Epub 2015 Oct 18. PMID: 26557393; PMCID: PMC4628690.
Copy Download .nbib Format: NLM
Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone.

Journal of clinical medicine research

Curtis G, Lewis AC.
PMID: 25247016
J Clin Med Res. 2014 Dec;6(6):429-34. doi: 10.14740/jocmr1855w. Epub 2014 Sep 09.

BACKGROUND: Toxidendron (poison ivy, oak, and sumac) contact dermatitis is a common complaint in the outpatient primary care setting with little evidence-based guidance on best treatment duration.METHODS: This randomized, controlled trial examined the efficacy and side effects of a...

Cite
Curtis G, Lewis AC. Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone. J Clin Med Res. 2014;6(6):429-34doi: 10.14740/jocmr1855w.
Curtis, G., & Lewis, A. C. (2014). Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone. Journal of clinical medicine research, 6(6), 429-34. https://doi.org/10.14740/jocmr1855w
Curtis, Gabrielle, and Lewis, Amy C. "Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone." Journal of clinical medicine research vol. 6,6 (2014): 429-34. doi: https://doi.org/10.14740/jocmr1855w
Curtis G, Lewis AC. Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone. J Clin Med Res. 2014 Dec;6(6):429-34. doi: 10.14740/jocmr1855w. Epub 2014 Sep 09. PMID: 25247016; PMCID: PMC4169084.
Copy Download .nbib Format: NLM
The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease.

NDT plus

Dalton K, Smith M, Thurman JM.
PMID: 25949427
NDT Plus. 2010 Aug;3(4):346-8. doi: 10.1093/ndtplus/sfq046. Epub 2010 Apr 13.

The transformation of lupus nephritis from one histologic pattern to another is well described. We report a case of a patient who initially presented with diffuse proliferative glomerulonephritis and was treated with prednisone and mycophenolate mofetil (MMF). She initially...

Cite
Dalton K, Smith M, Thurman JM. The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease. NDT Plus. 2010;3(4):346-8doi: 10.1093/ndtplus/sfq046.
Dalton, K., Smith, M., & Thurman, J. M. (2010). The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease. NDT plus, 3(4), 346-8. https://doi.org/10.1093/ndtplus/sfq046
Dalton, Kristen, et al. "The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease." NDT plus vol. 3,4 (2010): 346-8. doi: https://doi.org/10.1093/ndtplus/sfq046
Dalton K, Smith M, Thurman JM. The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease. NDT Plus. 2010 Aug;3(4):346-8. doi: 10.1093/ndtplus/sfq046. Epub 2010 Apr 13. PMID: 25949427; PMCID: PMC4421507.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 2623 entries